# Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

> **NCT05164614** · PHASE1 · COMPLETED · sponsor: **RANI Therapeutics** · enrollment: 50 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **COMBINATION_PRODUCT:** RT-102 (80 μg)
- **DRUG:** Forteo
- **COMBINATION_PRODUCT:** RT-102 (20 μg)

## Key facts

- **NCT ID:** NCT05164614
- **Lead sponsor:** RANI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-21
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-17
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164614, "Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05164614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*